There is growing evidence that an individual’s biome may have an impact upon their mental health. TRS-BIOME is an exploratory study investigating the differences in microbiomes of people who have a diagnosis of schizophrenia and are currently taking some form of antipsychotic. Schizophrenia is associated with a reduced microbial diversity but more research on this and its effects is required.

Up to a third of people diagnosed with schizophrenia will have treatment refractory schizophrenia defined as failing two trials of antipsychotics. These patients are often prescribed clozapine which is an effective antipsychotic but is known to cause cardiac, metabolic and haematological adverse effects.

The primary objective of this study is to compare the faecal microbiomes in treatment refractory schizophrenia patients who have responded to clozapine and patients to have not responded to clozapine. A total of 100 participants will be recruited within the Metro South Mental Health services.

This research is headed by Professor Dan Siskind (Metro South Addiction and Mental Health Service) and funded through PA Foundation. The Clinical Support Unit at QCMHR headed by Andrea Baker will coordinate the study.

This study is ongoing and looking for volunteers!   If you would like to participate in this study, please email Andrea Baker on

Other Projects

Cadence Discovery

Read more
SART Clinical Trial

Read more
H-RAP Observational Study

Read more
Cadence-COaST Clinical Trial

Read more

Contacting us

Do you want to know more about QCMHR, but can’t quite get enough information from our website? Please get in touch – we are happy to help!

Find out more

Send us a message